Vismodegib resistance in basal cell carcinoma: not a smooth fit.
Philadelphia, United States. In Cancer Cell, Apr 2015
In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.
Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance.
Mobile, United States. In Cancers (basel), 2014
The canonical hedgehog (HH) pathway is a multicomponent signaling cascade (HH, protein patched homolog 1 (PTCH1), smoothened (SMO)) that plays a pivotal role during embryonic development through activation of downstream effector molecules, namely glioma-associated oncogene homolog 1 (GLI1), GLI2 and GLI3.
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries.
Ann Arbor, United States. In Biomark Cancer, 2014
Some degree of controversy exists regarding the role of mutations affecting the sonic hedgehog (SHH) pathway, specifically Smoothened (SMO), which have been postulated to serve as either an alternative pathogenetic mechanism or secondary mutations.